Healthpeak Properties (DOC)
NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-09-04
$20.65-1.81%
Close 2026-09-04 · 1-day change
NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · DOC
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within real estate on a research-validated quality screen. As of 2026-09-04.
The screen ranks DOC against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 2 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue opportunistic capital recycling by selling stabilized outpatient medical assets and recapitalizing to fund higher growth opportunities and strengthen the balance sheet.
Stated as a priority in 4 of last 4 quarters. Healthpeak generated $267 million of proceeds from recapitalizations, dispositions, and loan repayments in 2026-Q1, increasing to $1.4 billion by 2026-Q2. Prior quarters showed steady asset sales and loan repayments totaling $160 million in 2025-Q3 and $349 million in 2025-Q4. The trajectory is delivering with substantial capital recycling proceeds supporting balance sheet strength and growth.
“Generated $1.4 billion of proceeds from Outpatient Medical recapitalizations, seller financing loan repayments, and dispositions during the second quarter and through August 3.”
“Generated $267 million of proceeds from recapitalizations, dispositions, and loan repayments.”
“Closed on $325 million of outpatient medical sales and received loan repayments totaling $24 million in the fourth quarter 2025.”
“Year-to-date asset sales and loan repayments totaling $160 million with $204 million of additional asset sales under contract.”
Expand Janus Living senior housing platform through acquisitions and IPO-related growth initiatives to leverage favorable market fundamentals.
Stated as a priority in 3 of last 4 quarters. Janus Living's revenue and Adjusted EBITDAre grew 35%-45% and 34%-42% year-over-year in 2026-Q1 and Q2. Senior housing acquisitions increased from $714 million in 2026-Q1 to approximately $1.0 billion by 2026-Q2. The trajectory is delivering with strong growth and acquisition activity supporting platform expansion.
“Janus Living reported year-over-year revenue and Adjusted EBITDAre growth of 45% and 34%, respectively; completed approximately $1.0 billion of senior housing acquisitions.”
“Janus Living completed its IPO in March 2026 and reported year-over-year consolidated revenue and Adjusted EBITDAre growth of 35% and 42%, respectively.”
“Acquired the remaining 46.5% joint venture partner’s interest in a 19-community senior housing portfolio for $314 million and entered into agreements for additional $360 million acquisitions.”
Focus on sustaining and improving same-store cash net operating income growth across outpatient medical, lab, and senior housing segments.
Stated as a priority in 4 of last 4 quarters. Total same-store cash NOI growth was 1.8% in 2026-Q2, 0.0% in 2026-Q1, 3.9% in 2025-Q4, and 0.9% in 2025-Q3. Outpatient medical and senior housing segments consistently showed positive growth. The trajectory is mixed but generally stable with modest growth in same-store NOI.
“Total same-store cash NOI growth of 1.8% with outpatient medical up 2.5% and senior housing up 19.2%.”
“Total same-store cash NOI growth of 0.0% with outpatient medical up 2.4% and senior housing up 13.8%.”
“Total merger-combined same-store cash NOI growth of 3.9% with outpatient medical up 4.1% and life plan up 16.7%.”
“Total merger-combined same-store cash NOI growth of 0.9% with outpatient medical up 2.0% and CCRC up 9.4%.”
Continue executing share repurchase programs to return capital to shareholders and optimize capital structure.
Stated as a priority in 3 of last 4 quarters. Healthpeak repurchased 5.9 million shares for approximately $100 million in 2026-Q1 and authorized a new $500 million share repurchase program in 2026-Q2. The program execution is ongoing and management has reiterated its commitment to share repurchases.
“Authorized new $500 million share repurchase program replacing existing authorization.”
“Repurchased 5.9 million common shares at a weighted average price of $16.81 for approximately $100 million under $500 million share repurchase program.”
“As of May 5, 2026, approximately $306 million remained available for share repurchases under the program.”
Advance technology innovation initiatives to improve automation, decision-making, and operational efficiency across the company.
Stated as a priority in 2 of last 4 quarters. Management highlighted technology innovation initiatives focused on automation and improved decision-making, with early rollout delivering a 5% reduction in G&A guidance in 2025-Q3. The trajectory shows initial progress with ongoing focus on operational efficiency.
“Technology innovation initiatives focused on automation, superior and faster decision-making, and better servicing our clients.”
“Early rollout of tech-enabled platform improved connectivity, data access, and productivity including 5% reduction in G&A guidance.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Real Estate names rated strong grew net income 57% of the time over the next year (vs 53% for the rest of the cohort, n=2778).
Over the trailing year it converted 2.94x of net income into operating cash flow. Historically, Real Estate names rated robust grew net income 63% of the time over the next year (vs 45% for the rest of the cohort, n=2211).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
12 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Real Estate names rated stable grew net income 43% of the time over the next year (vs 55% for the rest of the cohort, n=685).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.